Presse

Successful exit for HTGF: Miltenyi Biotec acquires biosensor company lino Biotech

16. März 2023

Zurich, March 16, 2023 – lino Biotech, a leading biosensor company and the world’s only provider of Focal Molography®, announced today it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023.

Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy manufacturing, and testing for off-target responses in living cells to support drug discovery.

Headquartered in Bergisch Gladbach, Miltenyi Biotec has been a global provider of products and services for biomedical research and cellular therapy for more than 30 years.

Under the terms of the transaction, Miltenyi Biotec will acquire 100% of the shares from the investors including Roche Venture Fund and High-Tech Gründerfonds (HTGF). The specific terms of the transaction were not disclosed. Brown Gibbons Lang & Company (BGL), acted as the exclusive financial advisor to lino Biotech.

lino´s innovative biosensor platform and Miltenyi’s cell and gene therapy approaches offer exciting synergies to lower the cost and establish a new standard for potency assays.

Dr. Mirko Stange, CEO of lino Biotech

The HTGF is very pleased that lino Biotech AG with its technically demanding project, which the HTGF III has advanced together with the founding team and Roche Venture, find its application within Miltenyi to complement a portfolio of technologies enabling drug discovery and cell therapy.

Dr. Martin Pfister, Principal at High-Tech Gründerfonds


About lino Biotech AG
lino Biotech AG was incorporated as ETH Zurich spin-out in Zürich, Switzerland, in March 2020, and is venture backed by Roche Venture Fund, High-Tech Gründerfonds and several life science family offices. lino Biotech is a life science tools company that develops reagent-free biosensors and readers to measure pharmaceutical relevant biological entities directly from crude samples such as bioprocess reactors solutions. The company’s ability to provide target-specific binding information in a faster, very sensitive and cost-effective manner can lower R&D and production cost for pharma and biotech customers and offers an opportunity to make novel Cell & Gene therapies accessible to more patients.

About Miltenyi Biotec B.V. & Co.KG
Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies offer solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, cancer, hematology, and graft engineering. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 4,500 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health. 

About High-Tech Gründerfonds  
The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected more than 4.5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 160 companies. 

Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. 

www.htgf.de/en 

Media contact 
High-Tech Gründerfonds Management GmbH 
Stefanie Grüter, Partner Communications & Relations  
T.: +49 228 – 82300 – 188 
s.grueter@htgf.de  

Immer aktuell informiert

Melde dich jetzt an und erhalte tagesaktuelle Pressemeldungen zu Investments sowie weitere Nachrichten rund um den High-Tech Gründerfonds. Wir berichten über wichtige Entwicklungen beim HTGF und über spannende Neuigkeiten aus unserem Portfolio. Ein erfolgreicher Exit, ein neues spannendes Investment oder Personalnews – du erfährst als Erstes davon!

Weitere Presse-Beiträge

Presse
29. Februar 2024

Digitaler Game Changer in der Mehrweg-Logistik – Spin-off Logistikbude gewinnt den Fraunhofer Gründerpreis 2023

Im Rahmen des Fraunhofer Symposiums »Netzwert« wurde der Fraunhofer-Gründerpreis 2023 an die Logistikbude GmbH verliehen: Prof. Dr. Holger Hanselka (Präsident Fraunhofer), Dr. Philipp Hüning (CEO und Co-Founder Logistikbude) und Dr. Alex von Frankenberg (Geschäftsführer HTGF) (v.l.n.r.) – Bild: Fraunhofer / Markus Jürgens Der mit 50.000 Euro dotierte Fraunhofer Gründerpreis 2023 geht an die Ausgründung Logistikbude GmbH. Deren Softwarelösung ermöglicht das vollständ
 
Presse
toolify founders
22. Februar 2024

1,6 Millionen Euro Investment für XITO: Seed-Finanzierung für leicht zugängliche Robotik

Für den Ausbau des Vertriebs und der Produktentwicklung stehen XITO mit der jetzt komplettierten Seed-Finanzierung 1,6 Millionen Euro zur Verfügung. Die Toolify Robotics GmbH ermöglicht Unternehmen mit ihrer Lösungs-Plattform XITO, Roboter eigenständig zu implementieren. Dank XITO gelingt insbesondere auch KMU der kostengünstige Einstieg in die Automatisierung – ohne Programmierkenntnisse und ohne Fachkräfte von außen. Ulm, 22. Februar 2024 – Das von den drei Robot
 
Presse
21. Februar 2024

ClimateTech-Startup Cyclize erhält für revolutionäres Kunststoff-Recycling rund €5 Millionen Seed-Finanzierung

Stuttgart, 21.2.2024 – Cyclize, das ClimateTech-Startup aus Stuttgart, geht mit €4,75 Millionen Startkapital voran, um eine Revolution in der chemischen Industrie einzuleiten. Ziel: Die Ablösung fossiler Ressourcen durch das innovative Recycling von Kohlenstoff aus Kunststoffabfällen und CO2. Geleitet wird die Finanzierungsrunde von UVC Partners. Komplementiert wird die Kapitalerhöhung durch High-Tech Gründerfonds (HTGF), Aurum Impact, UnternehmerTUM Funding for Innovators und Busine